ABL Diagnostics
ABLD
Company Profile
Business description
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
Contact
72c, rue de, WOIPPY
Thionville57140
FRAT: +33 783646850
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 December 2026
Employees
20
Stocks News & Analysis
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
stocks
Revenue growth on track for undervalued ASX healthcare stock
Near-term cost growth does not change our long-term view.
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,155.80 | 34.00 | 0.37% |
| CAC 40 | 8,313.17 | 67.38 | 0.82% |
| DAX 40 | 23,983.71 | 176.72 | 0.74% |
| Dow JONES (US) | 48,185.80 | 275.88 | 0.58% |
| FTSE 100 | 10,634.91 | 31.43 | 0.30% |
| HKSE | 25,893.54 | 141.14 | 0.55% |
| NASDAQ | 22,822.42 | 187.42 | 0.83% |
| Nikkei 225 | 56,924.11 | 1,028.79 | 1.84% |
| NZX 50 Index | 13,181.44 | 92.37 | -0.70% |
| S&P 500 | 6,824.66 | 41.85 | 0.62% |
| S&P/ASX 200 | 8,960.60 | 36.20 | 0.41% |
| SSE Composite Index | 3,986.22 | 20.05 | 0.51% |